JAM
BCRX icon

Jupiter Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Jupiter Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.4M Sell
1,196,371
-1,248
-0.1% -$9.69K 0.06% 267
2025
Q4 		$9.34M Sell
1,197,619
-858,296
-42% -$6.2M 0.07% 221
2025
Q3 		$15.6M Sell
2,055,915
-22,051
-1% -$184K 0.13% 179
2025
Q2 		$18.6M Sell
2,077,966
-71,003
-3% -$661K 0.16% 172
2025
Q1 		$16.1M Buy
2,148,969
+971,040
+82% +$7.83M 0.15% 183
2024
Q4 		$8.86M Buy
1,177,929
+108,030
+10% +$820K 0.09% 236
2024
Q3 		$8.13M Buy
+1,069,899
New +$8.13M 0.07% 242
2022
Q1 		– Sell
-62,704
Closed -$864K – 514
2021
Q4 		$864K Buy
+62,704
New +$830K 0.01% 424

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Jupiter Asset Management's BCRX Position: Q1 2026 in Review

Jupiter Asset Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 0.1% in Q1 2026, selling an estimated $9.69K and leaving 1,196,371 shares worth $11.4M. The position accounts for 0.06% of the portfolio, ranked #267.

Jupiter Asset Management first reported a position in BCRX in Q4 2021 and has held it in 8 quarters since. The position peaked at $18.6M in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Jupiter Asset Management held 1,196,371 shares of BioCryst Pharmaceuticals worth $11.4M as of Q1 2026.
  • Jupiter Asset Management sold 1,248 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $9.69K.
  • BioCryst Pharmaceuticals made up 0.06% of Jupiter Asset Management's portfolio in Q1 2026, its #267 holding.
  • Jupiter Asset Management first reported a position in BioCryst Pharmaceuticals in Q4 2021 and has held it in 8 quarters since.
  • Jupiter Asset Management's BioCryst Pharmaceuticals position peaked at $18.6M in Q2 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Jupiter Asset Management's 13F filing for Q1 2026, filed 12 May 2026.